Categories: News

Coherus BioSciences to Report First Quarter 2021 Financial Results on May 6th

REDWOOD CITY, Calif., April 30, 2021 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its first quarter 2021 financial results will be released after market close on Thursday, May 6, 2021. Starting at 4:30 p.m. ET, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

After releasing first quarter financial results, the Company will post them on the Coherus website at https://investors.coherus.com.

Conference Call Information

When: Thursday, May 6, 2021 starting at 4:30 p.m. ET
Dial-in: (800) 446-2782 (Toll-Free U.S. and Canada) or (847) 413-3235 (International)
Conference ID: 50149707
Webcast: https://investors.coherus.com/upcoming-events

Please dial-in 15 minutes early to ensure a timely connection to the call.

About Coherus BioSciences
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system.

For additional information, please visit www.coherus.com.

Coherus BioSciences Contact Information:
Investor Contact:
McDavid Stilwell, CFO
Coherus BioSciences, Inc.
IR@coherus.com

Staff

Recent Posts

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

2 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

2 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

2 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

2 hours ago

RxAnte Announces Strategic Growth Investment from Primus Capital

PORTLAND, Maine, Jan. 12, 2026 /PRNewswire/ -- RxAnte, the leading provider of analytics, software, and…

2 hours ago

PulseAI Secures Seed Funding to Advance AI-Driven ECG Diagnostics

BELFAST, Northern Ireland  , Jan. 12, 2026 /PRNewswire/ -- PulseAI, a rapidly emerging leader in…

2 hours ago